Table 6 Data Acquisition for the WATCH 410 Cohort
Summary Enrolment Data | Data Acquisition |
|---|---|
Demographics | 410 (100.0%) |
Anthropometry | 399 (97.3%) |
Asthma History | 409 (99.8%) |
Asthma Therapy | 407 (99.2%) |
Smoking History | 409 (99.8%) |
Co-morbid Disease History | 410 (100.0%) |
Questionnaires | |
 ACQ-6 | 371 (90.5%) |
 Hospital Anxiety & Depression Score (HADS) | 330 (80.5%) |
 Nijmegen | 289 (70.5%) |
 Sino-Nasal Outcome Score-22 (SNOT-22) | 250 (61.0%) |
 Hull Cough Hypersensitivity | 288 (70.2%) |
 EuroQoL-5QD | 72 (17.6%) |
 Epworth Sleepiness Score (ESS) | 332 (81.0%) |
 Medication Adherence Reporting Scale for Asthma (MARS-A) | 278 (67.8%) |
 Attention Control Score (ACS) | 357 (87.1%) |
 Mindful Attention Awareness Scale (MAAS) | 270 (65.9%) |
Blood Tests | |
 Peripheral eosinophil count | 401 (97.8%) |
 Total IgE | 399 (97.3%) |
 Aspergillus-specific IgE | 378 (92.2%) |
 Aspergillus precipitins IgG | 379 (92.4%) |
Lung Function Tests | |
 Pre-bronchodilator spirometry | 242 (59.0%) |
 Post-bronchodilator spirometry | 308 (75.1%) |
 Gas transfer | 234 (57.0%) |
 Plethysmography | 271 (66.1%) |
 Fractional exhaled nitric oxide (FeNO) | 307 (74.9%) |
Radiological Imaging | |
 High-resolution CT Chest | 262 (63.9%) |
 CT Sinuses | 53 (12.9%) |
 DEXA Scan | 127 (31.0%) |
Biobank Samples | |
 Bloods | 331 (80.7%) |
 Urine | 298 (72.7%) |